Brief: PMV Pharmaceuticals Announces First Patient Dosed In Global Tumor-Agnostic Phase 2 PYNNACLE Trial For Rezatapopt
27/03/2024 12:51
March 27 (Reuters) - PMV Pharmaceuticals Inc PMVP.O :
* PMV PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN
GLOBAL
TUMOR-AGNOSTIC PHASE 2 PYNNACLE TRIAL FOR REZATAPOPT IN TP53
Y220C-POSITIVE SOLID TUMORS
Source text for Eikon: ID:nGNX4y3tYS
Further company coverage: PMVP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pmv Pharmaceuticals
See all newsAustralia's Premier Investments jumps as Citi backs in-line earnings
U.S. STOCKS ON THE MOVE- Medtronic, Comstock, Apple
U.S. STOCKS ON THE MOVE-GoPro, TXNM Energy, Emergent BioSolutions
U.S. STOCKS ON THE MOVE-Fervo Energy, Myriad Genetics, Emergent BioSolutions
U.S. STOCKS ON THE MOVE-Robinhood Markets, Park Hotels & Resorts, Capricor Therapeutics